Krystal Biotech director trades 18,950 shares

Krystal Biotech, Inc. director Dino A. Rossi reported option exercises and related share sales.

Accepted by SEC EDGAR 02/23/2026 - 07:14 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Krystal Biotech, Inc. director Dino A. Rossi reported option exercises and related share sales. On February 19, 2026, he exercised stock options for 18,950 shares of common stock at $8.79 per share. The options vested ratably over four years beginning on June 1, 2018. On the same date, he sold 8,116 shares at $260.4858 and 10,834 shares at $262.10 in open-market transactions, totaling 18,950 shares sold. After these trades, he directly owned 78,691 shares of Krystal Biotech common stock.

Insider Trade Summary

Exercise and Sale: 18,950 shares ($4.79M approx. pre-tax spread)

Exercise and Sale 4 txns

Insider ROSSI DINO A

Role Director

Sold 18,950 shs ($4.95M)

Approx. gross sale proceeds $4.95M

Approx. exercise cost $167K

Approx. pre-tax spread $4.79M

Share of Position Sold 19.4%

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	18,950	$0.00	$0.00
Exercise	Common Stock	18,950	$8.79	$167K
Sale	Common Stock	8,116	$260.4858	$2.11M
Sale	Common Stock	10,834	$262.10	$2.84M

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 78,691 shares (Direct)

Holdings Before and After: Stock Option (Right to Buy), 18,950 to 0 contracts (Direct); Common Stock, 78,691 to 78,691 shares (Direct)

Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

1. F1. Multiple lots for the same price for this transaction have been combined.
2. F2. The options vested ratably over a four-year period beginning on June 1, 2018.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Krystal Biotech (KRYS) director Dino Rossi report?

Director Dino A. Rossi exercised options for 18,950 Krystal Biotech shares at $8.79 and sold 18,950 shares in open-market trades. Following these transactions, he held 78,691 shares of common stock directly.

How many Krystal Biotech (KRYS) shares did Dino Rossi sell on February 19, 2026?

On February 19, 2026, Dino A. Rossi sold a total of 18,950 Krystal Biotech common shares. He sold 8,116 shares at $260.4858 and 10,834 shares at $262.10 in open-market transactions.

What stock options did Dino Rossi exercise in the latest Krystal Biotech Form 4?

Dino A. Rossi exercised stock options covering 18,950 Krystal Biotech shares at an exercise price of $8.79 per share. These options vested ratably over a four-year period beginning on June 1, 2018.

How many Krystal Biotech (KRYS) shares does Dino Rossi own after these transactions?

After exercising options and selling 18,950 shares, Dino A. Rossi directly owns 78,691 Krystal Biotech common shares. This figure reflects his direct ownership reported following the February 19, 2026 transactions.

Were Dino Rossi’s Krystal Biotech option exercises linked to long-term vesting?

Yes. The options Dino A. Rossi exercised, covering 18,950 Krystal Biotech shares at $8.79, vested ratably over four years starting June 1, 2018. This indicates a long-term equity compensation structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROSSI DINO A

(Last) (First) (Middle)

C/O KRYSTAL BIOTECH, INC.

2100 WHARTON STREET, SUITE 701

(Street)

PITTSBURGH PA 15203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Krystal Biotech, Inc. [ KRYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		M		18,950	A	$8.79	97,641	D
Common Stock	02/19/2026		S		8,116	D	$260.4858	89,525	D
Common Stock	02/19/2026		S		10,834	D	$262.1(1)	78,691	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.79	02/19/2026		M			18,950	(2)	05/31/2027	Common Stock	18,950	$0	0	D

Explanation of Responses:

1. Multiple lots for the same price for this transaction have been combined.

2. The options vested ratably over a four-year period beginning on June 1, 2018.

Remarks:

	/s/ Krish Krishnan, as attorney-in-fact for Dino A. Rossi	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.